Survival in 20 patients with MSS/pMMR mCRC at a median follow-up of 15.4 months was 40% at 12 months; median...
EssilorLuxottica to acquire Optegra clinics,another leap forward in its med-tech strategy Acquisition of leading ophthalmology platform from MidEuropa will advance...
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless...
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two...
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of...
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- MUSE Microscopy, (the “Company”, “we”, “our”) a leader in slide-free, tissue-to-digital™ pathology...
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE:MLZ) (“MediPharm” or the “Company”), a...
WINNIPEG, Manitoba, May 29, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces...
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate...
Improved Sample Throughput, Automation Capabilities and Updated Hardware Design Cytek Aurora™ Evo Cytek today unveiled the Cytek Aurora™ Evo system,...
Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company’s Board of Directors Board and Management...
CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced...
Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patientsFRIENDSWOOD, Texas, May...
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing...
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation...
SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced...
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused...
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the...
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a...
LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized...